(Total Views: 119)
Posted On: 07/22/2019 12:30:47 PM
Post# of 127669

$CYCC News Article - Cyclacel Pharmaceuticals Announces First Patient Treated in a Phase 1/2 Study of Sapacitabine and Venetoclax in Relapsed or Refractory AML or MDS Patients https://marketwirenews.com/news-releases/cycl...84001.html


My Twitter: WhyteStocks